Login:
 
Sulphonylureas and the risk of adverse cardiovascular outcomes. Practitioner Sept 2018;262(1818):7

Sulphonylureas and the risk of adverse cardiovascular outcomes

24 Sep 2018Registered users

The use of sulphonylureas as a second-line substitution for metformin in type 2 diabetes is associated with increased rates of myocardial infarction (MI), all cause death and severe hypoglycaemia, a population-based cohort study has found. The study used data from the UK Clinical Practice Research Datalink (CPRD) to analyse a cohort of type 2 diabetes patients retrospectively. The CPRD contains medical records from more than 14 million patients registered at more than 680 general practices.

Registered usersThis article can only be accessed if you are a registered user of thepractitioner.co.uk or a subscriber to The Practitioner.

To buy this article (£25+tax) copy the article citation above and click Buy article